IBDEI1M7 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27018,2)
 ;;=^5009025
 ;;^UTILITY(U,$J,358.3,27019,0)
 ;;=L03.032^^132^1309^104
 ;;^UTILITY(U,$J,358.3,27019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27019,1,3,0)
 ;;=3^Cellulitis of Left Toe
 ;;^UTILITY(U,$J,358.3,27019,1,4,0)
 ;;=4^L03.032
 ;;^UTILITY(U,$J,358.3,27019,2)
 ;;=^5009026
 ;;^UTILITY(U,$J,358.3,27020,0)
 ;;=L03.041^^132^1309^26
 ;;^UTILITY(U,$J,358.3,27020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27020,1,3,0)
 ;;=3^Acute Lymphangitis of Right Toe
 ;;^UTILITY(U,$J,358.3,27020,1,4,0)
 ;;=4^L03.041
 ;;^UTILITY(U,$J,358.3,27020,2)
 ;;=^5009028
 ;;^UTILITY(U,$J,358.3,27021,0)
 ;;=L03.042^^132^1309^20
 ;;^UTILITY(U,$J,358.3,27021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27021,1,3,0)
 ;;=3^Acute Lymphangitis of Left Toe
 ;;^UTILITY(U,$J,358.3,27021,1,4,0)
 ;;=4^L03.042
 ;;^UTILITY(U,$J,358.3,27021,2)
 ;;=^5009029
 ;;^UTILITY(U,$J,358.3,27022,0)
 ;;=M34.0^^132^1309^249
 ;;^UTILITY(U,$J,358.3,27022,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27022,1,3,0)
 ;;=3^Progressive Systemic Sclerosis
 ;;^UTILITY(U,$J,358.3,27022,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,27022,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,27023,0)
 ;;=M34.1^^132^1309^91
 ;;^UTILITY(U,$J,358.3,27023,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27023,1,3,0)
 ;;=3^CR(E)ST Syndrome
 ;;^UTILITY(U,$J,358.3,27023,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,27023,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,27024,0)
 ;;=M34.2^^132^1309^273
 ;;^UTILITY(U,$J,358.3,27024,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27024,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,27024,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,27024,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,27025,0)
 ;;=M34.81^^132^1309^275
 ;;^UTILITY(U,$J,358.3,27025,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27025,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,27025,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,27025,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,27026,0)
 ;;=M34.82^^132^1309^276
 ;;^UTILITY(U,$J,358.3,27026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27026,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,27026,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,27026,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,27027,0)
 ;;=M34.83^^132^1309^277
 ;;^UTILITY(U,$J,358.3,27027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27027,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,27027,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,27027,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,27028,0)
 ;;=M34.89^^132^1309^274
 ;;^UTILITY(U,$J,358.3,27028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27028,1,3,0)
 ;;=3^Systemic Sclerosis NEC
 ;;^UTILITY(U,$J,358.3,27028,1,4,0)
 ;;=4^M34.89
 ;;^UTILITY(U,$J,358.3,27028,2)
 ;;=^5011784
 ;;^UTILITY(U,$J,358.3,27029,0)
 ;;=M34.9^^132^1309^278
 ;;^UTILITY(U,$J,358.3,27029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27029,1,3,0)
 ;;=3^Systemic Sclerosis,Unspec
 ;;^UTILITY(U,$J,358.3,27029,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,27029,2)
 ;;=^5011785
 ;;^UTILITY(U,$J,358.3,27030,0)
 ;;=R21.^^132^1309^257
 ;;^UTILITY(U,$J,358.3,27030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27030,1,3,0)
 ;;=3^Rash/Nonspecific Skin Eruption
 ;;^UTILITY(U,$J,358.3,27030,1,4,0)
 ;;=4^R21.
 ;;^UTILITY(U,$J,358.3,27030,2)
 ;;=^5019283
 ;;^UTILITY(U,$J,358.3,27031,0)
 ;;=R23.3^^132^1309^269
 ;;^UTILITY(U,$J,358.3,27031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27031,1,3,0)
 ;;=3^Spontaneous Ecchymoses
 ;;^UTILITY(U,$J,358.3,27031,1,4,0)
 ;;=4^R23.3
 ;;^UTILITY(U,$J,358.3,27031,2)
 ;;=^5019295
